scholarly journals Adipokines, C-Reactive Protein and Lipid Profile Levels in Hypertensive Type 2 Diabetic Portuguese Patients

2014 ◽  
pp. 1-9 ◽  
Author(s):  
Maria Neuparth ◽  
Jorge Proença ◽  
Alice Santos-Silva ◽  
Susana Coimbra
Keyword(s):  
Lipid Profile ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Type 2 Diabetic

scholarly journals Effect of sitagliptin and glimepiride on C-reactive protein (CRP) in overweight Type-2 diabetic patients

2019 ◽  
Vol 35 (2) ◽  
Author(s):  
Mazhar Hussain ◽  
Muhammad Amir Rafique ◽  
Javed Iqbal ◽  
Lubna Akhtar
Keyword(s):  
Lipid Profile ◽  
Blood Sugar ◽  
Diabetic Patients ◽  
C Reactive Protein ◽  
Type 2 Diabetic Patients ◽  
Reactive Protein ◽  
Anti Inflammatory ◽  
Type 2 Diabetic ◽  
Inflammatory Effect

Objectives: To compare the anti-inflammatory effect of sitagliptin and glimepiride by measuring CRP in overweight Type-2 diabetic patients. Methods: This clinical trial was conducted at diabetic clinic of Islam Central Hospital, Sialkot over a period of six months from June to November 2017. A total of 110 overweight Type-2 diabetic patients were divided in to two groups. Group-A was given tablet sitagliptin 50mg while Group-B was given tablet glimepiride 2mg for a period of 12 weeks. The dose was titrated according to blood sugar level. The primary outcome was measuring changes in CRP while secondary outcomes was changes in BMI, blood sugar, HbA1C, lipid profile and CRP from baseline in both study group using SPSS 16. Results: After 12 weeks treatment, body weight increased in glimepiride but slightly reduced in sitagliptin, however comparison between them was non significant (p=0.07). Although both groups reduced blood sugar and HbA1c but comparison between them was non significant (p=0.59 and p=0.17 respectively) value. However lipid profile improved significantly in sitagliptin vs. glimepiride group i.e total cholesterol (-25±32.5 vs +1.5±45.4 P=0.02) triglycerides (-19±44.6 vs-1.8±48.7 P=0.001) LDL- cholesterol (-10±22.4 vs-0.8±18.7 P=0.001) HDL-cholesterol (-2.6±6.2 vs 1.2±5.2 P=0.03).Sitagliptin significantly reduced CRP in comparison to glimepiride (-2.3±1.8 vs0.8±1.5 P=0.001). Conclusion: Sitagliptin has strong anti inflammatory effect marked by reduction in CRP level in comparison to glimepiride in overweight type-2 diabetic patients. It also exerted beneficial effect on glycemic and lipid profiles. How to cite this:Hussain M, Rafique MA, Iqbal J, Akhtar L. Effect of sitagliptin and glimepiride on C-reactive protein (CRP) in overweight Type-2 diabetic patients. Pak J Med Sci. 2019;35(2):---------. doi: https://doi.org/10.12669/pjms.35.2.645 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

scholarly journals CLINICAL SIGNIFICANCE OF PROCALCITONIN AND C-REACTIVE PROTEIN IN THE PREDICTION OF CARDIOVASCULAR COMPLICATIONS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

2017 ◽  
Vol 10 (9) ◽  
pp. 297
Author(s):  
Hanaa H. Ahmed ◽  
Wafaa Gh Shousha ◽  
Hatem A El Mezayen ◽  
Ibrahim A Emara ◽  
Marwa E Hassan
Keyword(s):  
Roc Curve ◽  
Cardiovascular Complication ◽  
Curve Analysis ◽  
Diabetic Patients ◽  
C Reactive Protein ◽  
Roc Curve Analysis ◽  
Reactive Protein ◽  
The Mean ◽  
Type 2 Diabetic

  Objective: This work was delineated to assess procalcitonin (PCT) and C-reactive protein (CRP) as prognostic markers for cardiovascular complication in type 2 diabetic patients.Methods: Forty diabetic patients without cardiovascular disease (CVD), 40 diabetic patients with CVD, and 20 healthy control counterparts were participated in this study. Serum PCT and CRP levels were assayed and correlated with metabolic parameters. Receiver operating characteristic (ROC) curve analysis was done for each biochemical marker.Results: The mean level of PCT was 707.17±99.19 ng/l in diabetic patients versus 881.30±123.56 ng/l for the cardio-diabetic patients (p<0.0001). The mean value of CRP was 34.43±17.27 mg/l in diabetic patients versus 50.32±20.19 mg/l for the cardio-diabetic patients (p=0.0003). PCT levels were significantly amplified in the cardio-diabetic patients with increasing CRP, triglycerides (TG), fasting blood glucose (FBG), and cholesterol (p=0.004, 0.0005, 0.002, and 0.01, respectively). CRP levels were significantly enhanced in the cardio-diabetic patients with increasing TG, FBG, cholesterol, and microalbumin (p=0.002, 0.047, 0.003, and 0.001 respectively). ROC curve analysis for PCT and CRP revealed that the area under curve (AUC) was 0.878 and 0.727, respectively. These findings indicate the good validity of the above biomarkers especially PCT as a prognostic marker for cardiovascular complication in type 2 diabetic patients.Conclusion: This study evidences the usefulness of measuring serum levels of PCT and CRP in diagnosis of cardiovascular complication in type 2 diabetic patients.

scholarly journals Evaluation of Serum High Sensitivity C-reactive Protein (hs-CRP) In Type-2 Diabetic Patient

1970 ◽  
Vol 11 (1) ◽  
pp. 20-23
Author(s):  
AKM Fazlul Haque ◽  
ARM Saifuddin Ekram ◽  
Quazi Tarikul Islam ◽  
Md Sarwar Jahan ◽  
Md Zahirul Haque
Keyword(s):  
Type 2 Diabetes ◽  
Diabetic Patient ◽  
Healthy Subjects ◽  
High Sensitivity ◽  
Diabetic Patients ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Hs Crp ◽  
Type 2 Diabetic

Type-2 diabetes may remain in subclinical form for years before diagnosis. This quiescence of type-2 diabetes is a great concern for health care providers. The earliest change of the type-2 diabetes is the insulin resistance, which is associated with the increased macrovascular risk due to induction of chronic inflammation in the vessels of the body which leads to atherosclerotic change in the vessels. High sensitivity CRP (hs-CRP) is the measure of C-reactive protein with greater accuracy and the lower limit of its assay is .01 mg/L which is more than 100 times as sensitive as the usual CRP measurement (lower limit 5 mg/L). The median level of hs-CRP from blood samples of apparent healthy subjects is 0.8 mg/L. For this, physician uses the hs-CRP parameter as a marker of chronic inflammation in apparently normal healthy individuals, specially for the assessment of atherosclerosis, which is a chronic inflammatory procedure from the very beginning, in type-2 diabetic, obese and hypertensive patients. This vascular atherosclerosis assessment help them to calculate the cardiovascular as well as cerebrovascular risk of those patients. To help the type-2 diabetic patients from the very begining in respect of the prognostic view of the macrovascular risk, estimations of serum hs-CRP in the early stage of these patient may be a enthusiastic one. This descriptive study was carried out by choosing 70 diabetic patient who had no other comorbidity or any complications of diabetes and 35 healthy subjects who were neither diabetic nor had any diseases. Both the groups were non-smoker and non-alcoholic and non-hypertensive, hs-CRP level was measured in both the groups along with the HbA1c%. The mean hs-CRP in diabetic group was 1.13 mg/L and in normal healthy subjects was 0.39 mg/L. This higher level of mean hs-CRP (1.13 mg/L) in diabetic patients is statisticaly significant (P<0.01) compared with that of the normal healthy subjects mean hs-CRP (0.39 mg/L). This mean level of hs-CRP in normal healthy subjects was below the lower level of cardiovascular risk (1 mg/L). Keywords: High sensitivity CRP, C-reactive protein, diabetes DOI:10.3329/jom.v11i1.4263 J Medicine 2010: 11: 20-23

Sign in / Sign up

Export Citation Format

Share Document